About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

COMPLETEDPhase 2

A Study of the Effect of Gemcitabine With Fish Oil in Patients With Advanced Pancreatic Cancer

Phase II Trial of the Effect of Gemcitabine With Intravenous Omega-3 Fish Oil Infusion in Patients With Unresectable Pancreatic Adenocarcinoma

NCT01019382•University Hospitals, Leicester

View on ClinicalTrials.gov

AI summary by Clareo Health

Generating AI summary...

Conditions

Pancreatic Neoplasms

Interventions

Lipidem fish oil infusion + Gemcitabine chemotherapy

Locations

1

United Kingdom

Locations (1)

University Hospitals of Leicester : Leicester Royal Infirmary

Leicester, Leicestershire, United Kingdom

Key Dates

Start Date

October 1, 2009

Primary Completion Date

June 1, 2014

Completion Date

June 1, 2014

Last Updated

December 4, 2014

Related Studies

RECRUITINGPhase 1

Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma

NCT06885697

MesotheliomaNeoplasms+6 more

Preoperative EUS Elastography for Pancreatic Texture and POPF Prediction After PD

NCT07139236

Pancreatic NeoplasmsPancreatic Fistula

Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques

NCT07035587

Lung NeoplasmsPancreatic Neoplasms+6 more

Intraoperative Hypotension in Pancreatoduodenectomy: A Randomized Trial of General Versus Combined Anesthesia

NCT06953193

Pancreatic NeoplasmsHypotension+1 more

RECRUITINGPhase 1/2

Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer

NCT05218889

Pancreatic CancerPDAC - Pancreatic Ductal Adenocarcinoma+2 more

RECRUITINGPhase 2

Oxaliplatin Combined With Irinotecan Liposome Injection II Through Hepatic Artery Infusion (HAIC) Followed by 5-FU/LV (HAIC) or Tegorgor Oral Combination Therapy for Hepatic Metastasis of Pancreatic Cancer

NCT06538623

Pancreatic NeoplasmsNeoplasm Metastasis+1 more

View all related studies

Sponsors

Lead Sponsor

University Hospitals, Leicester

Collaborators

B. Braun Medical Inc.

Detailed Description

Full Eligibility Criteria

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 4, 2014Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions